BEAT (HeartBeam) Other Long Term Assets: $0.06 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAT HeartBeam Inc BEAT
26 GF Score
Price $0.43
! 2 Warning Signs
View Full Analysis

What is HeartBeam Other Long Term Assets?

HeartBeam BEAT -2.26% 26 Other Long Term Assets is $0.06 Mil as of Jun. 2026. GuruFocus rates BEAT with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

HeartBeam's other long-term assets for the quarter that ended in Jun. 2026 was $0.06 Mil.

HeartBeam's quarterly other long-term assets declined from Dec. 2025 ($0.06 Mil) to Mar. 2026 ($0.06 Mil) but then increased from Mar. 2026 ($0.06 Mil) to Jun. 2026 ($0.06 Mil).

HeartBeam's annual other long-term assets increased from Dec. 2023 ($0.05 Mil) to Dec. 2024 ($0.06 Mil) and increased from Dec. 2024 ($0.06 Mil) to Dec. 2025 ($0.06 Mil).

HeartBeam Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for HeartBeam's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartBeam Other Long Term Assets Chart

HeartBeam Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial 0.00 0.00 0.05 0.06 0.06

HeartBeam Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.06 0.06 0.06
BEAT
26GF Score
HeartBeam Inc BEAT
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeartBeam Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.06 Mil mean?
HeartBeam (BEAT) has a Other Long Term Assets of $0.06 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on HeartBeam and its competitors.
Is HeartBeam's Other Long Term Assets too high?
HeartBeam's current Other Long Term Assets is $0.06 Mil. Overall, HeartBeam has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does HeartBeam's Other Long Term Assets compare to CRVW and ONMD?
HeartBeam's Other Long Term Assets of $0.06 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Healthcare Providers & Services company?
A good Other Long Term Assets depends on the Healthcare Providers & Services industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on HeartBeam and its competitors. HeartBeam's current Other Long Term Assets is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartBeam stock overvalued right now?
HeartBeam (BEAT) has a current Other Long Term Assets of $0.06 Mil. The current Other Long Term Assets is $0.06 Mil. HeartBeam's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For HeartBeam (BEAT), the current Other Long Term Assets is $0.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeartBeam Business Description

Address 2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
26GF Score

Get the complete analysis for BEAT

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price